Research Publications
- McGahan, L. Pembrolizumab (Keytruda®) as first-line therapy for PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No. 91. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; October 2019.
- McGahan, L. Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs). Horizon Scanning in Oncology No. 89. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; July 2019.
- McGahan, L. Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triplenegative breast cancer (aTNBC). Horizon Scanning in Oncology No. 87. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; March 2019.
- McGahan, L. Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenstrom’s macroglobulinemia. Horizon Scanning in Oncology No. 85. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; December 2018.
- McGahan, L. Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No 83. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; September 2018.
- McGahan, L. Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No 80 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; June 2018.
- McGahan, L. Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). Horizon Scanning in Oncology No 78 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; February 2018.
- McGahan, L. Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small cell lung cancer after prior chemoradiotherapy. Horizon Scanning in Oncology No 76 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; December 2017.
- McGahan, L. Olaparib (Lynparza®️) in patients with BRCA-mutated metastatic breast cancer. Horizon Scanning in Oncology No 71 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; September 2017.
- McGahan, L. Ceritinib (Zykadia™) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. Horizon Scanning in Oncology No 69 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; June 2017.
- McGahan, L. Atezolizumab (Tecentriq®️) in previously treated non-small cell lung cancer (NSCLC). Horizon Scanning in Oncology No 68 ISSN-online 2076-5940. Vienna: Ludwig Boltzman Institute for Health Technology Assessment; April 2017.
- McGahan, L. Palbociclib (Ibrance™) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. Horizon Scanning in Oncology No 64 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; January 2017.
- McGahan, L. Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. Horizon Scanning in Oncology No 61 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; October 2016.
- Lambert, R, Vreugdenburg, TD, Marlow, N, Scott, NA, McGahan, L, Tivey, D. Practical applications of rapid review methods in the development of Australian health policy. Australian Health Review; accepted for publication 5 June 2016, published online 29 July 2016.
- Best practices for increasing attendance at outpatient addictions clinics. Rapid Review August 2015. Canadian Centre for Substance Abuse, freely accessible with login through the Treatment Space at http://www.eenetconnect.ca/g/treatment
- McGahan, L, Scott, A. Hysteroscopy for abnormal uterine bleeding: review of clinical evidence and guidelines. Rapid Review March 2015. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
- McGahan, L, Scott, A. Tonsillectomy, adenoidectomy and adenotonsillectomy for obstructive sleep apnoea: review of clinical evidence and guidelines. Rapid Review February 2015. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
- Lopez-Olivo, MA, Amezaga Urruela, M, McGahan, L, Pollono, E.N., Suarez-Almazor, M.E. Rituxumab for rheumatoid arthritis (Review). Cochrane Database of Systematic Reviews 2015, Issue 1. Art.No.: CD007356. DOI: 10.1002/14651858.CD007356.pub2.
- McGahan, L, Scott, A. Arthroscopy for knee osteoarthritis: review of clinical evidence and guidelines. Rapid Review August 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
- McGahan, L, Scott, A. Herniorrhaphy for inguinal and femoral hernia: review of clinical evidence and guidelines.Rapid Review December 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
- Poulin, P., Chapman, K., McGahan, L., Austen, L., Schuler, T. Pre-operative skin antiseptics for preventing surgical site infections: what to do? Operating Room Nurses Association of Canada Journal; 32:3 (2014), 14-29.
- McGahan, L, Scott, A. Spinal surgery for chronic low back pain: review of clinical evidence and guidelines. Rapid Review June 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
- McGahan, L, Scott, A. Centralisation of bariatric surgery: policy implications. Rapid Review March 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
- McGahan, L. Point-of-care phenotypic and genetic testing for patients with acute coronary syndrome. Issues in Emerging Health Technologies issue 123. Ottawa: Canadian Agency for Drugs and Technologies in Health; March 2013.
- McGahan, L. Afrezza inhaled insulin for diabetes mellitus. Issues in Emerging Health Technologies issue 120. Ottawa: Canadian Agency for Drugs and Technologies in Health; January 2013.
- McGahan, L. Hearing screening in pre-school aged children: a review of the clinical effectiveness and guidelines. Health Technology Inquiry Service Level 2. Ottawa: Canadian Agency for Drugs and Technologies in Health; November 2012.
- McGahan, L. Metal-on-metal total hip replacements or hip resurfacing for adults: a review of clinical effectiveness and cost-effectiveness. Health Technology Inquiry Service Level 2. Ottawa: Canadian Agency for Drugs and Technologies in Health; November 2012.
- McGahan, L. Sterile pre-filled saline syringes for acute care patients: a review of clinical evidence, cost-effectiveness, evidence-based guidelines and safety. Health Technology Inquiry Service Level 2. Ottawa: Canadian Agency for Drugs and Technologies in Health; July 2012.
- McGahan, L. Hydroxocobalamin for cyanide poisoning in the pre-hospital setting: a review of the comparative clinical effectiveness [CADTH HTIS-level 2 review June 2012]
- McGahan, L. Buspirone for the treatment of anxiety: a review of clinical effectiveness, safety, and cost-effectiveness [CADTH HTIS-level 2 review May 2012]
- McGahan, L. Opioid management practices for the prevention of drug diversion and misuse: a review of the clinical evidence and guidelines [CADTH HTIS-level 2 review April 2012]
- McGahan, L. Triptans for migraine headaches: a review on safety [CADTH HTIS-level 2 review March 2012]
- Clinical and pharmacoeconomic review report [CADTH Common Drug Review March 2012]
- McGahan, L. Lipid lowering agents for stroke prevention: a review of the clinical evidence, safety and guidelines. [CADTH HTIS-level 2 review, March 2012]
- Clinical and pharmacoeconomic review report [CADTH Common Drug Review Feb 2012]
- McGahan, L. Topical oxygen treatment for wound healing: a review of clinical and cost-effectiveness. [CADTH HTIS-level 2 review Jan 2012]
- McGahan, L. Populations requiring foldable lenses for cataract surgery: a review of clinical evidence and guidelines. [CADTH HTIS-level 2 review, Oct 2011]
- McGahan, L. The use of oxyNEO® and oxyContin® in adults: a review of the evidence on safety. [CADTH HTIS-level 2 review Sept 2011]
- Clinical and pharmacoeconomic review report [CADTH Common Drug Review- Sept 2011]
- McGahan, L. Acetylsalicylic acid for venous thromboembolism prophylaxis: a review of clinical evidence, benefits, and harms.[CADTH HTIS –level 2 review Aug 2011]
- McGahan, L., Antiplatelet agents for acute coronary syndrome: a review of the guidelines and recommendations. [CADTH HTIS –level 2 review, Aug 2011]
- Kamel, C., McGahan, L., Polisena, J., Mierzwinski-Urban, M., Embil, J. Preoperative skin antiseptic preparations for preventing surgical site infections: a systematic review. Infection Control and Hospital Epidemiology; 33:6 (2012), 608-617.
- McGahan, L., Kamel, C., Mierzwinski-Urban, M. Preoperative skin antiseptic preparations and application techniques for preventing surgical site infections: a systematic review of the clinical evidence and guidelines. [CADTH HTIS –level 3 review, June 2011]
- McGahan, L., Calibration of blood glucose monitors for diabetes: a review of the clinical evidence and guidelines. [CADTH HTIS-level 2 review, June 2011]
- Clinical and pharmacoeconomic review report [CADTH Common Drug Review- Jan 2011]
- Clinical and pharmacoeconomic review report [CADTH Common Drug Review- Nov 2010/Jan 2011/Oct 2011]
- McGahan, L. Methods to screen for hemoglobin S in blood donors selected for exchange transfusions: a review of the clinical effectiveness and guidelines. [CADTH HTIS –level 2 review, July 2010]
- Hodge, W., Brown, A., Kymes, S., Cruess, A., Blackhouse, G., Hopkins, R., McGahan, L., Sharma, S., Pan, I., Blair, J., Vollman, D. Pharmacological management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol 2010;45:223-30.
- Banerjee, S., Brown, A., McGahan, L., Asakawa, K., Hutton, B., Clark, M., Severn, M., Sharma, M., Cox, J.L. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses. [Technology report number 133]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.
- Chen, S.Y., Russell, E., Banerjee, S., Hutton, B, Brown, A., Asakawa, K., McGahan, L., Clark, M., Severn, M., Cox, J., Sharma, M. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses. [Technology report number 131]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.
- Banerjee, S., Brown, A., Hutton, B., McGahan, L., Asakawa, K., Clark, M., Cox, JL., Sharma, M. Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses. [Technology report number 123]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
- McGahan, L. Mechanical cardiopulmonary resuscitation versus manual cardiopulmonary resuscitation for cardiac arrest in pre-hospital and hospital settings. [CADTH HTIS –level 2 review dated 30 May 2008]
- McGahan, L. Diagnosis and treatment of autism: guidelines and clinical effectiveness. [CADTH HTIS –level 2 review dated 30 April 2008]
- McGahan, L. Administration of intravenous medications to pediatric patients: guidelines and safety of intravenous push.[CADTH HTIS –level 2 review dated 4 April 2008].
- Brown, A., Hodge, W., Kymes, S., Cruess, A., Blackhouse, G., Hopkins, R., McGahan, L., Sharma, S., Pan, I., Blair, J., Vollman, D., Morrison, A. Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation. [Technology report number 110]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
- McGahan, L. Continuous erythropoietin receptor activator (Mircera) for renal anemia. Issues in Emerging Health Technologies issue 113. Ottawa: Canadian Agency for Drugs and technologies in Health; 2008.
- Wells, P., Brown, A., Jaffey, J. McGahan, L., Poon, M, Cimon, K. 2007 Oct 116. Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis. Open Medicine [Online] 1:3. Available:
- McGahan, L. Cholesterol testing devices: clinical and cost-effectiveness. [CADTH HTIS –level 2 review dated 19 February 2008].
- McGahan, L. Outpatient pulmonary vein ablation for atrial fibrillation: clinical and cost-effectiveness review. [CADTH HTIS –level 2 review dated 3 December 2007].
- McGahan, L. and M. Severn. Comparative clinical effectiveness and safety of long-term subcutaneous insulin injections by site. [CADTH HTIS –level 1 review dated 30 August 2007].
- Membe, S., McGahan, L., Cimon, K., Gawal, M., Giammarco, R., Mierzwinski-Urban, M. Triptans for acute migraine: comparative clinical effectiveness and cost-effectiveness [Technology report no 76]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
- Brown, A., Wells, P., Jaffey, J., McGahan, L., Poon, M-C., Cimon, K., Campbell, K. Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost-effectiveness [Technology report no 72.]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
- McGahan, L., and R. Banks. Aspheric and blue light-filtering intraocular lenses in patients with presbyopia and cataracts. [CADTH HTIS –level 1 review dated 7 December 2006].
- Palylyk-Colwell, E. and L. McGahan. Rituximab for rheumatoid arthritis. Issues in Emerging Health Technologies issue 89. Ottawa: Canadian Agency for Drugs and Technologies in Health; September 2006.
- McGahan, L. and T. Keating. Hospital policy and formulary restrictions to reduce Clostridium difficile-associated diarrhea (CDAD). [CADTH HTIS –level 2 review dated 12 May 2006]
- Guidelines for economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006. L. McGahan drafted information regarding the evaluation of non-drug technologies.
- McGahan, L., Mierzwinski-Urban, M., Keating, T. Rituximab selective CD+ B-cell depletion therapy for rheumatoid arthritis: a systematic review of clinical trials. [CCOHTA HTIS –level 3 review dated 31 March 2006.]
- McGahan, L., Kakuma R., Ho, C., Bassett, K., Noorani, H.Z., Joyce, J., Allanson, J., Taylor, S. BRCA1 and BRCA2 predictive genetic testing for breast and ovarian cancers: a systematic review of clinical evidence [Technology report no. 66]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006.
- Hailey, D., Tran, K., Dales, R., Mensinkai, S. McGahan, L. Recommendations and supporting evidence in guidelines for referral of patients to sleep laboratories. Sleep Medicine Reviews 2006; 10: 287-299.
- Hailey, D., Tran, K., Dales, R., Mensinkai, S., McGahan, L. A review of guidelines for referral of patients to sleep laboratories [Technology report no. 55]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005.
- Garces, K., McCormick, A., McGahan, L., Skidmore, B. Botulinum toxin A for upper and lower limb spasticity: a systematic review. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2004. Technology report no. 51.
- Brady, B., McGahan, L., Skidmore, B. A systematic review of economic evidence on stroke rehabilitation services. International Journal of Technology Assessment in Health Care; 21:1 (2005), 15-21.
- Noorani, H.Z., Brady, B., McGahan, L., Teasell, R., Skidmore, B., Doherty, T.J. Stroke rehabilitation services: systematic reviews of the clinical and economic evidence. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2003. Technology report no 35.
- Grunfeld, E., Noorani, H.Z., McGahan, L., Paszat, L., Coyle, D., van Walraven, C., Joyce, J., Sawka, C. Surveillance mammography after treatment of primary breast cancer: a systematic review. The Breast 2002; 11(3):228-35.
- L. McGahan. Continuous glucose monitoring in the management of diabetes mellitus. Issues in Emerging Health Technologies. 2002; May; (32)1-4.
- L. McGahan. Behavioural interventions for preschool children with autism. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2001. Technology Report no 18.
- Paszat, L., Grunfeld, E., van Walraven, C., Coyle, D., Sawka, C., Yun, J., McGahan, L., Noorani, HZ. A population-based cohort study of surveillance mammography after treatment of primary breast cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2001. Technology Report no 15.
- L. McGahan. Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction. Issues in Emerging Health Technologies. 2001; Jan; (13)1-4.
- L. McGahan. Lotronex: therapy for diarrhea predominant irritable bowel syndrome. Issues in Emerging Health Technologies. 2000; Oct; (11)1-4.
- McGahan, L. and H.Z. Noorani. Surveillance mammography after treatment for primary breast cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000.
- L. McGahan. Etanercept: anti-tumour necrosis factor therapy for rheumatoid arthritis. Issues in Emerging Health Technologies. 1999; Oct; (8)1-4.
- Noorani, H.Z. and L. McGahan. Criteria for selection of adult recipients for heart, cadaveric kidney, and liver transplantation. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1999.
- Noorani, H.Z. and L. McGahan. Predictive genetic testing for breast and prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1999.
- L. McGahan. The Heart Laser: transmyocardial revascularization treatment of angina pectoris. Issues in Emerging Health Technologies. 1998; (5)1-4.
- L. McGahan. Herceptin: monoclonal antibody therapy for metastatic breast cancer. Issues in Emerging Health Technologies.1998; (4)1-4.
- Noorani, H.Z. and L. McGahan. Ethical, psycho-social and policy implications arising from predictive genetic testing for breast and prostate cancer. Health Law Review. 98/99; 7(3):14-15.
L. McGahan Consulting / Ottawa, ON, Canada / T: 613 867 5497 / E: [email protected]
Content Copyright 2013 L. McGahan Consulting. All rights reserved.